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Background: The completeness of resection is a key prognostic indicator in patients with ovarian cancer, and
the application of tumour-targeted fluorescence image-guided surgery (FIGS) has led to improved detection
of peritoneal metastases during cytoreductive surgery. CD24 is highly expressed in ovarian cancer and has
been shown to be a suitable biomarker for tumour-targeted imaging.
Methods: CD24 expression was investigated in cell lines and heterogenous patient-derived xenograft (PDX)
tumour samples of high-grade serous ovarian carcinoma (HGSOC). After conjugation of the monoclonal anti-
body CD24 to the NIR dye Alexa Fluor 750 and the evaluation of the optimal pharmacological parameters
(OV-90, n = 21), orthotopic HGSOC metastatic xenografts (OV-90, n = 16) underwent cytoreductive surgery
with real-time feedback. The impact of intraoperative CD24-targeted fluorescence guidance was compared
to white light and palpation alone, and the recurrence of disease was monitored post-operatively (OV-90,
n = 12). CD24-AF750 was further evaluated in four clinically annotated orthotopic PDX models of metastatic
HGSOC, to validate the translational potential for intraoperative guidance.
Findings: CD24-targeted intraoperative NIR FIGS significantly (473%) improved tumour detection and resec-
tion, and reduced the post-operative tumour burden compared to standard white-light surgery in orthotopic
HGSOC xenografts. CD24-AF750 allowed identification of minuscule tumour lesions which were undetect-
able with the naked eye in four HGSOC PDX.
Interpretation: CD24-targeted FIGS has translational potential as an aid to improve debulking surgery of ovar-
ian cancer.
Funding: This study was supported by the H2020 program MSCA-ITN [675743], Helse Vest RHF, and Helse
Bergen HF [911809, 911852, 912171, 240222, 911974, HV1269], as well as by The Norwegian Cancer Society
[182735], and The Research Council of Norway through its Centres of excellence funding scheme [223250,
262652].
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
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High-grade serous ovarian carcinoma (HGSOC) is the most com-
mon epithelial ovarian cancer (EOC) subtype and accounts for 80% of
ovarian cancer deaths. Standard of care therapy typically consists ofcytoreductive surgery followed by platinum-based chemotherapy.
Recent progress in surgical efforts and the addition of anti-angiogenic
agents and poly ADP-ribose polymerase (PARP) inhibitors as mainte-
nance therapy for select patient groups have improved progression
free survival [1]. However, despite these improvements the 5-year
survival rate for HGSOC is still below 50%, with only modest increase
of long-term survival rates over the last decades. Amongst the
research priorities suggested for HGSOC to reduce mortality are
enhanced definition of biomarkers which can predict surgical
Research in context
Evidence before this study
Ongoing clinical trials for folate-targeted fluorescence image-
guided surgery (FIGS) in women with ovarian cancer are prom-
ising, and the improved detection of peritoneal lesions during
cytoreductive surgery manifests hope of better outcome for
these patients. Biomarkers which can distinguish malignancy
from normal tissue with high specificity and sensitivity are a
requirement for fluorescence assisted resections, and bio-
markers of progenitor cells and metastasis are particularly rele-
vant for debulking surgery of ovarian cancer. HER2, FSH, VEGF
and osteonectin have all been evaluated as biomarkers for FIGS
in preclinical EOC models. To further expand the palette of
theranostic contrast agents available to surgeons in the intrao-
perative setting, we have investigated CD24, a stem cell marker,
as a novel target for fluorescence-guided cytoreduction of ovar-
ian cancer.
Added value of this study
We have demonstrated the benefit of CD24-targeted near-
infrared FIGS in clinically relevant orthotopic xenograft and
patient-derived xenograft models for high-grade serous ovar-
ian carcinoma.
Implications of all the available evidence
We anticipate that the use of CD24-targeted FIGS will aid fur-
ther delineation of metastases and be of greater benefit to ovar-
ian cancer patients with poor prognosis. CD24 is overexpressed
in many other solid tumours, highlighting the potential of
CD24-FIGS as an aid during surgical resection of other cancers.
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eductive surgery represents the cornerstone of HGSOC therapy, with
the volume of residual disease representing one of the most impor-
tant prognostic factors for these patients [3]. Thus, the ultimate surgi-
cal goal in HGSOC is complete tumour resection, which unlike disease
stage and molecular subtype, is the only clinical criteria influenced by
the surgeon [4]. However, despite the efforts of the most skilled sur-
gical practitioners, the impact of complete resection is also highly
dependent on the patient’s inherent tumour biology, immune status,
and it is routinely hampered by disseminated carcinomatosis of the
peritoneal cavity [5,6]. Consequently, the benefit and attributed com-
plications of aggressive and radical upfront debulking surgery is cur-
rently being addressed by the TRUST international trial [7].
While significant efforts are currently being employed in the risk-
stratification of patients that are most likely to benefit from immuno-
therapy [8] and those that will relapse following optimal surgery
[3,7,9], improvement in surgical planning and imaging are also being
developed [10]. Intraoperative imaging modalities for surgical guid-
ance include ultrasound, x-ray fluoroscopic imaging, computed
tomography (CT) or magnetic resonance imaging (MRI) [11]. How-
ever, these modalities are not tumour specific, and given the imprac-
ticality and cost of these techniques in the operative setting,
surgeons still rely on subjective visual inspection and palpation of tis-
sues intraoperatively to achieve complete resection. Thus, there is a
critical need for more objective and practical technologies to increase
the degree of cytoreduction for the vast majority of patients.
Fluorescence image-guided surgery (FIGS) is a relatively novel
intraoperative molecular imaging modality to enter the surgical the-
atre [11,12]. FIGS exploits fluorescent contrast agents that label
tumours either directly by binding to tumour biomarkers, orindirectly by accumulation due to enhanced permeability and reten-
tion (EPR) effect in solid tumours, resulting in dramatically enhanced
visualisation of cancerous lesions, thus providing surgeons real-time
guidance when performing complex oncologic resections [11,13,14].
Near-infrared (NIR) emitting fluorophores (700900 nm) provide
optimal contrast owing to low photon absorption, scattering, photo-
bleaching and tissue autofluorescence, which maximises tissue pene-
tration depth [15]. In addition, NIR fluorescence is invisible to the
naked eye, and therefore does not impede the surgical field or opera-
tive procedures. van Dam et al. performed the first in-human clinical
trial of FIGS targeting the folate receptor alpha (FRa) in patients with
EOC [16,17]. Subsequently, a NIR conjugated probe of FRa (OTL38)
has been examined in phase I and II clinical trials in EOC patients,
demonstrating improved cytoreduction [18,19]. FIGS studies in pre-
clinical EOC models have identified HER2, FSH, VEGF and osteonectin
as alternative targets to folate [2023], further expanding the palette
of theranostic contrast agents amenable to surgeons in the intraoper-
ative setting.
In the current study, we evaluate CD24, a small, heavily glycosy-
lated, mucin-like cell surface protein which has been identified as a
stem cell marker in ovarian cancer [24], as a target for NIR FIGS in
orthotopic xenograft models of metastatic HGSOC. We have previ-
ously demonstrated the usefulness of non-invasive fluorescence
imaging with CD24 conjugated to Alexa Fluor 680 [25], but due to
autofluorescence in the 700 nm wavelength range during abdominal
intraoperative imaging, we conjugated the human specific monoclo-
nal antibody targeting CD24 to the longer wavelength NIR fluoro-
phore Alexa Fluor 750 (CD24-AF750) in the current study. In vitro
verification of CD24-AF750 targeting and subsequent in vivo pharma-
cokinetic and pharmacodynamic profiling of CD24-AF750 deter-
mined optimal contrast conditions for FIGS. We demonstrated the
ability of CD24-AF750 to not only target primary tumours but also
delineate local and distant metastases in relevant orthotopic xeno-
graft models. Furthermore, we evaluated the impact of preclinical
intraoperative FIGS with CD24-AF750 to improve surgical guidance
and increase cytoreduction. Finally, we demonstrate the translational
potential of CD24-AF750 to target heterogeneous patient-derived
xenograft models of HGSOC.
2. Materials and methods
2.1. Conjugation of CD24-AF750 probe
The monoclonal mouse anti-human CD24 antibody (clone SN3,
cat# MCA1379ELX, RRID: AB_321526, Bio-Rad, Oxfordshire, UK) was
conjugated to Alexa Fluor 750 NHS ester using the SAIVITM rapid
antibody labelling kit and purified by size exclusion chromatography
as described by the manufacturer (cat# S30046, Invitrogen, Carlsbad,
USA). The spectral characteristics of the resulting protein, CD24-
AF750, was determined (Supplementary Fig S1a; λab = 753 § 3 nm,
λem = 778 § 2 nm) by Spark 20 M (Tecan, M€annendorf, Switerland)
and the final conjugate concentration (16 mg/ml), the degree of
labelling (DOL = 326 § 004) and the protein recovery (68 § 735%)
was measured and calculated photometrically by the One UVVis
spectrophotometer (λ280 protein/λ753 dye, Thermo ScientificTM, Wal-
tham, USA). The conjugation efficiency and the purity of the conju-
gate were further validated by high performance liquid
chromatography (HPLC). High resolution size exclusion chromatogra-
phy was performed using a 46 mm ID £ 300 cm L TSK gel Super
SW3000 column and a 46 mm ID £ 35 cm L Guard (part numbers
18675 and 18762, Tosoh Bioscience, Griesheim, Germany) with an
optimal separation range for globular proteins of 10500 kDa. The
analysis was carried out using 01 mol/L Na2SO4 in 01 mol/L Phos-
phate buffer at pH 67 as mobile phase with a flow rate of 035 mL/
min (Thermo ScientificTM DionexTM UltiMateTM LPG-3400SD Pump).
A Thermo ScientificTM DionexTM UltiMateTM 3000 Rapid Separation
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and the data were collected and processed employing the
ChromeleonTM Chromatography Data System (CDS) Software (version
7.2.10). Based on the elution volumes and times (not shown)
obtained for the different analytes (CD24, AF750 and CD24-AF750)
no traces of free dye were present in the conjugate sample (Supple-
mentary Fig. S1b).
2.2. Cell lines and cell culture
Human EOC cell lines Caov-3 (cat# HTB-75, RRID: CVCL_0201),
OV-90 (cat# CRL-11732, RRID: CVCL_3768), and Skov-3 (cat# HTB-
77, RRID: CVCL_0532) were obtained from the American Type Culture
Collection (ATCC Manassas, VA, USA), and COV318 (cat# 07071903,
RRID: CVCL_2419) from Sigma Aldrich (Sigma Aldrich, St. Louis, USA).
The cell lines were cultured in RPMI 1640 (OV-90) and DMEM (Caov-
3, Skov-3 and COV318) media supplemented with 10% heat-inacti-
vated FBS and 1% L-glutamine for at least one week (37 passages)
before included into in vitro or in vivo studies (RPMI cat# R5886,
DMEM cat# D5671, Sigma Aldrich) (FBS cat# 10270106, L-Glutamine
cat# 25030081, Gibco, Paisley, UK). Mycoplasma testing was per-
formed using the MycoAlertTM PLUS assay (cat# LT07-705, Lonza,
Walkersville, USA). All cell lines were transduced to express green
fluorescent protein (GFP) and red-shifted Luciola Italica luciferase;
performed according to the manufacturers protocol using the Redi-
Fect Red-FLuc-GFP lentiviral particles (cat# CLS960003, Perkin Elmer,
Waltham, MA, USA). Stable expression of luciferase allowed for non-
invasive in vivo monitoring of tumour growth by bioluminescence
imaging.
2.3. Patient material
Patient-derived xenograft (PDX) models of HGSOC were devel-
oped from tumour tissue obtained from chemotherapy naïve patients
with primary advanced disease, admitted to the Department of
Obstetrics and Gynaecology, Haukeland University, Bergen, Norway.
The tumour specimens were included in the Bergen Gynaecologic
Cancer Biobank. Informed consent was obtained from the women
before collection of the fresh tumour samples. The regional commit-
tees for medical and health research ethics (REC West) has approved
the biobank and the study (Reference IDs: 2014/1907, 2015/548 and
2017/612). Resected tumour samples were processed immediately.
Tumour samples were cut into small pieces (2 mm3) using a sterile
scalpel and washed with phosphate buffered saline (PBS). Tissue
pieces were enzymatically dissociated for two hours with collagenase
II (cat# 17101015, 300 U/mL, Gibco) supplemented with 3 mM activ-
ity stabiliser CaCl2, followed by addition of TrypLE (cat# 12604013,
Gibco) on continuous agitation for 10 min (250 rpm, 37 °C). Dissoci-
ated cells were strained, washed with PBS, checked for cell viability
with trypan blue staining, and stored in freezing medium (90% FBS,
10% DMSO) at 150 °C.
2.4. Flow cytometry analysis
EOC cell suspensions (OV-90, Caov-3, COV318 and Skov-3) were
detached from culture flasks with 1£ trypsin (cat# T3924, Sigma
Aldrich), washed, and re-suspended in FACS staining buffer (PBS sup-
plemented with 5% FBS and 2 mM EDTA). Before staining, 2 £ 105
cells were incubated with 10% human FcR blocking reagent (cat #
130-059-901, Miltenyi Biotec, Bergisch Gladbach, Germany) for
5 min and stained with CD24-AF750 (1 mg) in a staining volume of
100 mL for 20 min at 4 °C. Mouse anti-human CD24-PE (clone SN3,
75 mL/037 mg, cat # LS-C105830, RRID: AB_1053866, LS Bio, Seat-
tle, USA) was used as a positive control. All samples were washed
twice with FACS staining buffer and acquired with the BD Fortessa
Flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).Quantitative determination of CD24 expression of OV-90 cells,
expressed as antibody-binding capacity (ABC) units, was per-
formed by using a bead calibration kit (Qifikit cat# K007811-8,
Dako Agilent, Santa Clara, USA). 105 cells were re-suspended in
100 mL FACS buffer and stained with a saturated concentration of
5 mg unconjugated mouse anti-human CD24 for 45 min at 4 °C.
An unconjugated monoclonal CD33 IgG1 antibody (Clone WM53,
Cat# MCA1271T, RRID: AB_2074234, Bio-Rad) was used as a neg-
ative control. Cells, set-up beads and calibration beads were
washed with PBS-BSA-Azide buffer twice and stained with a sec-
ondary FITC conjugate (provided in the Qifikit) for 45 min at 4 °C.
After two further washing steps, samples were acquired and
recorded with the BD Fortessa Flow cytometer.
2.5. In vitro targeting of CD24
The binding affinity of CD24-AF750 to EOC cell lines (OV-90, Caov-
3, COV318 and Skov-3) was determined by optical fluorescent imag-
ing (FLI), and comparison of CD24-AF750 to CD24-IRDye 800CW was
performed after conjugation of the mAb CD24 to IRDye 800CW NHS
ester (cat# 929-70020, lot# C90927-04, LI-COR, Lincoln, NE, USA)
with a DOL of 33. Briefly, cells were detached, washed and
25 £ 106 cells were stained with 1mg of either CD24-AF750 (as pre-
viously described), or CD24-IRDye 800CW. Cells were washed twice
and kept in cell pellets without supernatant before being imaged
with the IVIS Spectrum In Vivo Imaging System, PerkinElmer, using
the filter settings λex = 745 § 15 nm, λem = 800 § 10 nm, and NIR
channel #2 in the FLARE intraoperative near-infrared fluorescence
imaging system RP1 (Fluorescence-Assisted Resection and Explora-
tion imaging system, Curadel LLC, Marlborough, USA), which has a
laser excitation source λex = 760 § 3 nm and an imaging filter 
781 nm (Supplementary Fig. S1a).
2.6. In vitro cell proliferation assay at different CD24-AF750
concentrations
In vitro OV-90 cell proliferation was evaluated in the presence of
1010 107 M CD24-AF750 to test the safety of the conjugate. A
water soluble tetrazolium salts (WST-1) assay (cat # 5015944001,
Roche Applied Science, Pensberg, Germany) was used to validate cell
proliferation 48 h after the incubation with four different CD24-
AF750 concentrations (4 h after WST-1 incubation) and performed
according to the manufacturers protocol and as previously described
[25]. The spectrophotometrically measured formazan signal concen-
tration of all metabolically active cells of all samples were normalised
to 48-h cultures of OV-90 cells without CD24-AF750.
2.7. In vivo xenograft models of ovarian cancer
All animal experiments were conducted in compliance with the
procedures of the Norwegian State Commission for Laboratory Ani-
mals, the European Convention for the Protection of Vertebrates
Used for Scientific Purposes and approved by the Norwegian Food
Safety Authority (Application ID 14128). Female NOD-scid IL2rgnull
(NSG) mice (aged 8 to 12-weeks, weight 2259 § 208 g; Vivarium,
University of Bergen) were maintained under defined floral condi-
tions and housed in individually ventilated (HEPA-filtered air) cages
at the University of Bergen’s animal facility. No more than five mice
were in each individually ventilated cage, which was kept on a 12-h
dark/night schedule at a constant temperature of 21 °C and at 50%
relative humidity. Bedding and cages were autoclaved and changed
twice per month, and the mice had continuous supply of sterile water
and food. The animals were monitored daily by the same personnel
for the duration of the experiment and weighed twice weekly. Activ-
ity levels, appearance, food intake and post-operative wounds were
monitored, and humane endpoints were defined with the use of
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institutional guidelines.
2.7.1. Subcutaneous xenograft model
The NSG mice were injected with 5 £ 106 OV-90luc+ cells re-sus-
pended in 150 mL 1:1 saline/matrigel mix (cat# 08-774-391, Corning
Inc, Fisher Scientific, Waltham, USA) subcutaneously in the left
flank under 35% sevoflurane anaesthesia (cat# 29960 SevoFlo, Zoe-
tis, Louvain-la-Neuve, Belgium). Mice were included in FLI experi-
ments when the calliper measurements reached 200 mm3
(Volume = (height £width £ length £ p)/6).
2.7.2. Orthotopic xenograft model
Mice were anaesthetised as described above and placed in left lat-
eral recumbence. A combination protocol for analgesia, including
01 mg/kg buprenorphine hydrochloride (cat# 561634 Temgesic,
Indivor UK Ltd, Slough, Berks, Great Britain) and 5 mg/kg meloxicam
(cat# 386860 Metacam vet., Boehringer Ingelheim Animal Health
Nordics, Copenhagen, Denmark) was administered subcutaneously.
The fur on the right flank was shaved and the skin was prepared
aseptically with chlorhexidine 5 mg/mL (cat# 007169 Fresenius Kabi,
Halden, Norway). The surgical procedure was performed as previ-
ously described [26], with the following modifications; 105 OV-90luc+
cells or single cell suspensions from four different primary tumours
were separately mixed with matrigel (1:1, cat# 08-774-391, Corning
Inc, Fisher Scientific, Waltham, USA) and injected into the bursa of
the ovary at the level of the oviduct, using a 30 G needle. Abdominal
muscles and skin were closed separately, using 60 absorbable poly-
glactin suture (cat# V492H Vicryl, Ethicon, Johnson & Johnson, Bel-
gium). The animals were given a subcutaneous injection of sterile
saline and allowed to recover in a warm environment, before return-
ing to the home cage.
2.8. In vivo imaging
2.8.1. Bioluminescence imaging
Bioluminescence imaging (BLI) was performed using the IVIS
Spectrum In Vivo Imaging System, 10 min after intraperitoneal
administration of 150 mg/kg of D-luciferin (cat# L-8220, Biosynth,
Staad, Switzerland). Tumour progression for animals xenografted
with luciferase positive OV-90luc+ cell lines was monitored weekly
following injection, and after debulking surgery.
2.8.2. Fluorescence imaging
CD24-AF750 at a concentration of 3 mg/g mouse bodyweight was
injected intravenously into the tail vein. FLI was performed with the
IVIS Spectrum In Vivo Imaging System with a 745 § 15 nm excitation
bandpass filter and 800 § 10 nm emission bandpass filter, 48 h after
monoclonal antibody administration, or as indicated. All scans were
acquired with epi-illumination and auto exposure. For biolumines-
cence and fluorescence optical imaging data, region of interests (ROI)
were manually gated around the tumour, the organ, the background
(muscle) or the whole ventral and lateral positioned mouse and cal-
culated using the Living image software (Perkin Elmer). The mean
fluorescence intensity and tumour to background ratio was calcu-
lated at different time points.
2.8.3. Intraoperative NIR fluorescence imaging
Intraoperative imaging was performed using the FLARE intrao-
perative NIR fluorescence imaging system (Curadel LLC). Acquisition
of CD24-AF750 fluorescence was conducted using NIR channel #2, as
described above; exposure time was set to 500 ms and gain to 1. The
colour video channel has a 400660 nm illumination source; expo-
sure time was set to 8.5 ms. Both images were simultaneously
acquired and merged as a pseudo-coloured image. The imaging head
was positioned at 245 cm working distance, resulting in a field ofview (FOV) of 77 cm2 (no zoom). Intraoperative images were ana-
lysed using ImageJ (Fiji, version 1.52p,) and the FLARE internal analy-
sis software (V3.5.0). The fluorescence intensity was measured in
arbitrary units (A.U.) and illustrated as mean fluorescence intensity.
Tumour to background ratios (TBR), liver to background ratios (LBR)
and tumour to liver ratios (TLR) were measured using the FLARE soft-
ware, the background was defined as the signal intensity of the adja-
cent tissue or muscle.
2.8.4. Determination of NIR optimal contrast
For the in vivo CD24-AF750 biodistribution (n = 9), dose finding
study (n = 12, 1 mg, 2 mg, 3 mg and 4 mg antibody per gram mouse
bodyweight) and patient-derived xenograft models (n = 10), mice
were injected intravenously with CD24-AF750 48 h prior to imaging,
or as otherwise indicated. Anaesthesia was provided as described for
the surgical protocols. A midline coelitomy was performed, and intra-
operative CD24-AF750 fluorescence imaging was performed as
described above. Mice were euthanised, and tumours and abdominal
organs were imaged ex vivo with the FLARE system and IVIS for con-
firmation of fluorescence specificity. Resected tumour tissue was
inoculated in D-luciferin for 10 min and BLI (IVIS) was performed for
confirmation of OV-90luc+ origin.
2.8.5. Intraoperative FIGS  survival study
Orthotopically engrafted OV-90luc+ mice (n = 16) were used as a
model for the cytoreductive survival surgeries. After four weeks, once
an ovarian tumour had established and disseminated to the surround-
ing tissues, the animals were randomised into two surgical groups;
CD24 fluorescent image-guided (n = 8) or control white light surgery
(n = 8). Mice assigned to FIGS (n = 8) were then injected with 3 mg/g
CD24-AF750 48 h pre-operatively. The anaesthetic and analgesic pro-
tocol is described above, in addition the mice received infiltration
anaesthesia of the incision line with a combination of 10 mg/kg lido-
caine and 3 mg/kg bupivacaine (cat# 0839006 Bupivicaine Accord and
(cat# 579092 Lidocaine Accord, Accord Healthcare AB, Solna, Sweden).
The animal was placed in dorsal recumbence, the surgical area was
prepared aseptically as described above, and a midline coeliotomy was
performed. Abdominal exploration to assess the extent of the tumour
load was performed based on visual inspection and palpation of tissues
and the main tumour burden was considered resectable in all mice,
lesions on vital organs (when present) were not resected. The control
group underwent ovariohysterectomy and tumour resection based on
this assessment. In the CD24-targeted fluorescence image-guided sur-
gery group, the laser excitation source (λex = 760 § 3 nm, Supplemen-
tary Fig. S1a) was deployed after initial exploration, and tumour
resection was performed with fluorescence guidance. The abdominal
cavity and skin were closed in two layers with a continuous suture of
60 absorbable polyglactin. Postoperatively, all animals were given a
subcutaneous injection of sterile saline and allowed to recover in a
warm environment. The resected tumour tissue was imaged with the
FLARE system for fluorescence verification, and then by BLI as
described above to confirm OV-90luc+ origin. The post-mortem exami-
nation included macroscopic description of primary and metastatic
tumours, and ex vivo bioluminescence and fluorescence imaging of
explanted organs. Tumour lesions were submitted for histopatholog-
ical analysis. FIGS image analysis was performed as described above.
2.8.6. Preclinical disease staging
We developed a modified staging system, based on the FIGO stag-
ing classification for cancer of the ovary, fallopian tube and peritoneum
[4], and allocated a disease stage from I to IV for each mouse, based
on the extent of the disease seen in pre-surgical whole-body biolumi-
nescence images and the intraoperative assessment, where stage I
indicates local disease only, stage II indicates disease within the pel-
vic cavity, stage III indicates disease present in elsewhere in the
abdominal cavity and stage IV indicates the presence of disease
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by BLI and sacrificed in accordance to the study endpoints and insti-
tutional guidelines.
2.9. Immunohistochemistry
Resected tissue samples were fixed in 4% paraformaldehyde and
embedded in paraffin. Formalin fixed paraffin embedded (FFPE) sam-
ples were sectioned and prepared for immunohistochemical staining of
rabbit anti-human antibodies: CD24 (Cat# ab199140, Clone: polyclonal,
1:2000, Abcam, Cambridge, UK), CK8 (Cat# ab193094, Clone: EP1628Y,
1:1500, Abcam) and folate receptor alpha (Cat# PA5-24186, clone
SA170417DD, 1:2000, Invitrogen). Deparaffinisation was done manu-
ally for 20min in xylene, and hydrated through 100%, 95% and 70% eth-
anol to water. Antigen retrieval was done by cooking the slides for
15 min in citrate buffer (pH 60) in the microwave. The DAKO Envision
protocol was used for the immunohistochemistry procedure. Rabbit
specific polymer-HRP was used in order to avoid false-positive mouse-
mouse cross bindings in the mouse tissue. Stained tissue sections were
evaluated using an immunoreactivity scoring system defined by the
sum of staining intensity (1 = weak, 2 =moderate, 3 = strong) and stain-
ing extent (0 = 0%, 1 = 15%, 2 = 625%, 3 = 2675%, 4 = 76100%)
resulting in an immunoreactivity score (IRS) of 07 [27]. Ovarian tissue
from a healthy mouse of the same breed and age was used as control,
the sample was prepared as described above and stained with CD24.
2.10. Statistical analysis
Statistical analysis was performed using the GraphPad Prism soft-
ware (Version 60, La Jolla, CA, USA). To test for significant differenceFig. 1. CD24 is highly expressed in ovarian cancer cell lines and primary ovarian cancer cell
cell lines OV-90, Caov-3, COV318 and Skov-3 stained with the monoclonal antibody CD24 co
sion was evaluated by flow cytometry, and antigen-binding capacity was quantified for OV-9
binding. White light (colour) image, near infrared (NIR 800) fluorescent image and pseudo
(25 £ 107 tumour cells, scale bar = 1 cm). (d) Immunohistochemistry of four different patien
score (IRS) 425 § 096 (scale: 1ow = 1  7 = high). Images were captured at 100£ and 200£between two variables, we used ordinary one-way ANOVA with two-
tailed nonparametric unpaired MannWhitney U test. P-values
<005 were regarded statistically significant. All data with error bars
is presented as mean § standard deviation.
3. Results
3.1. CD24 expression in EOC cell lines and patient-derived tumour cells
We have previously demonstrated that CD24 is a suitable target
for non-invasive molecular imaging of EOC [25]. To determine the
targeting capacity and intraoperative detectability of the CD24-
AF750 tracer, we investigated the expression of CD24 in clinically rel-
evant cell lines and patient-derived xenograft tumours. In vitro
expression of CD24 in EOC cell lines OV-90, Caov-3, COV318 and
Skov-3 was assessed after staining with CD24-AF750, and flow cyto-
metric analysis revealed heterogeneous expression among cell lines
(Fig. 1(a)). Quantitative determination of antigenic CD24 expression
in the OV-90 cell line by flow cytometry revealed more than 300,000
CD24 binding sites per cell (Fig. 1(b)). Heterogeneous mean fluores-
cence intensity (MFI) results of CD24-AF750 stained cell pellets
(25 £ 106 tumour cells) was observed in the same four HGSOC cell
lines when imaging was performed with the NIR fluorescence intrao-
perative system, and the CD24 expression correlated with that of the
flow cytometry results. Comparison of the MFI with cell pellets
stained with CD24-IRDye 800CW revealed significantly lower MFI
(1181 § 1012 AF750 vs34 § 314 IRDye 800CW, p = 0.0005), which
is likely the result of suboptimal excitation of the IRDye 800CW
(Fig. 1(c)). To further elucidate CD24 as a target for FIGS in the clinical
setting, we performed immunohistochemistry on four differents, and can be detected by CD24-AF750 NIR staining. (a) Flow cytometry analysis of EOC
njugated to AF750 (n = 3). Each column represents the mean with SD. (b) CD24 expres-
0 compared to monoclonal IgG1 antibody (mAb) control. (c) Validation of target-specific
-coloured fluorescence intensity merge image of CD24-AF750 stained EOC cell pellets
t-derived xenograft (PDX) ovarian tumours, stained with anti-CD24. Immunoreactivity
magnification (scale bar = 25mm).
6 K. Kleinmanns et al. / EBioMedicine 56 (2020) 102783orthotopically implanted PDX tumours, which demonstrated CD24
expression (IRS 425 § 096; score: low = 1  7 = high) in patient-
derived HGSOC samples (Fig. 1(d)). Finally, the safety of the CD24-
AF750 conjugate was assessed in vitro by quantification of prolifer-
ative cells, and the assay demonstrated that increasing concentra-
tions of CD24-AF750 have no effect on cell proliferation
(Supplementary Fig. S1c).
3.2. Determination of optimal imaging parameters in vivo
3.2.1. Biodistribution of CD24-AF750
Having determined that CD24 is highly expressed in the majority
of HGSOC preclinical samples analysed, we aimed to identify the opti-
mal pharmacological parameters towards FIGS application in vivo.
We evaluated the in vivo biodistribution of CD24-AF750 in an ortho-
topic and subcutaneous OV-90luc+ xenograft model by optical non-
invasive FLI imaging, performed at 24-h intervals, and BLI imagingFig. 2. Biodistribution and pharmacokinetics of CD24-AF750. (a) Representative example of
neous and orthotopic xenograft model, performed at 24-h intervals, and bioluminescence i
fluorescence from CD24-AF750 in the subcutaneous tumour, the orthoptic tumour, liver and
images of the CD24-AF750 fluorescence in the primary tumour (marked by the dashed line)
coloured fluorescence intensity merge image. PT= primary tumour, L= liver. Tumour to backg
sue as background (red circle) (d) Comparison of in vivo primary tumour mean fluorescence
and pseudo-coloured fluorescent signal merge image of the primary tumour, kidney and liv
ments. Statistical analysis (one-way ANOVA with unpaired MannWhitney U test) with p <was performed to verify tumour specificity in the FLI scans (n = 3)
(Fig. 2(a)). Orthotopic and subcutaneous tumours could be identified
after 24 h, but the background fluorescence from the bladder, liver
and kidneys were most prevalent at this time point. CD24-AF750
fluorescence in orthotopic and subcutaneous tumours reached their
maximum after 48 h and 72 h, respectively, whilst the background
fluorescence in the kidney and liver decreased from 24 h after admin-
istration. The tumour to background ratio (TBR) was calculated,
showing a TBR of 547 § 092 and 632 § 344 at 48 h and
542 § 138 and 816 § 513 at 72 h for the orthotopic and subcuta-
neous tumour respectively (Fig 2(b)). Therefore, intraoperative in
vivo imaging was performed after 48 (n = 3) and 72 (n = 3) hours, and
the mean fluorescence intensity (MFI) and TBR in the primary tumour
were compared, whereby an area of abdominal muscle was selected
as background (Fig. 2(c)). In vivo the ovarian tumour MFI
(10236 § 2055) and TBR (277 § 097) were higher at 48 h com-
pared to 72 h (MFI 8109 § 2875 and TBR 268 § 099) (Fig. 2(d)).longitudinal whole-body fluorescence imaging with CD24-AF750 in an OV-90 subcuta-
maging (BLI) for confirmation of tumour specificity. (b) Timepoint analysis of the total
kidney (n = 3) identified 24 and 48 h as most advantageous. (c) Intraoperative in vivo
at 48 and 72 h, showing white light colour image, NIR fluorescence image and pseudo-
round ratios (TBR) were calculated using the mean fluorescence intensity of muscle tis-
intensity (measured in arbitrary units; A.U.) and TBR. (e) Representative colour, NIR 800
er (all delineated by the dashed lines) at 48 and 72 h, used for (f) ex vivo MFI measure-
005 (*) were regarded as statistically significant. (Scale bars = 1 cm).
K. Kleinmanns et al. / EBioMedicine 56 (2020) 102783 7CD24 expression was confirmed by IHC in the fluorescence positive
OV-90luc+ xenografted tumours, (IRS 45 § 07; score: Low = 1 
7 = high) (Supplementary Fig. S2a), and a healthy mouse ovary (NSG)
was used as negative control (Supplementary Fig. S2b). Ex vivo mea-
surement of the ovarian tumour MFI was 6140 § 3602 at 48 h and
7529 § 5225 at 72 h, whilst the liver MFI was 5163 § 490 at 48 h
and 3083 § 1950 at 72 h, and the kidney MFI was 1526 § 558 at
48 h and 1528 § 2011 at 72 h (Fig. 2(e) and (f)). Ex vivo comparison
of all organs is presented in Supplementary Fig. S3a. Ex vivo optical
BLI and FLI confirmed fluorescence specificity (Supplementary Fig.
S3b). The optimal time point for intraoperative imaging was identi-
fied as 48 h after CD24-AF750 injection, although tumours could be
detected up to 120 h, demonstrating the long retention time of
CD24-AF750 (Fig. 2(a) and (b)).
3.2.2. Determination of optimal CD24-AF750 dose
Based on our previous work [28], we identified four different
doses of CD24-AF750 (1, 2, 3 and 4 mg per gram mouse bodyweight)
to be compared in vivo for optimal intraoperative visualisation ofFig. 3. Determination of the optimal dose for CD24-targeted intraoperative imaging. (a) Intr
and pseudo-coloured fluorescence intensity merge image of representative orthotopic OV-9
(PT= primary tumour, marked by white dashed line, and L = liver). (b) Comparison of CD24
1 mg vs 3 mg) and tumour to background ratio (TBR) (p = 0.0142 for 1 mg vs 3 mg; p = 0.029
vivo colour, NIR 800 and pseudo-coloured fluorescent signal merge image of the primary tum
MFI of the organs between the four different doses. (p = 0.0222 for 1mg vs 4mg). Statistical a
regarded as statistically significant. (Scale bars = 1 cm).orthotopic OV-90luc+ tumours (n = 3 mice per dose). When metastatic
disease was detected by BLI, tumour-bearing mice were injected
with CD24-AF750 and intraoperative imaging performed 48 h later
(Fig. 3(a)). While tumour fluorescence showed a significant increase
in MFI (4574 § 2076, 9403 § 1397, 10018 § 406 and
12599 § 6594 respectively) with increasing antibody concentra-
tion, similar increases in background were also observed (Fig. 3(a)
and (b)). The observed dose response effect may be resultant of sev-
eral factors e.g. saturation of CD24 receptor binding sites on tumour
cells, fluorescence quenching and nonspecific background binding,
leading to increased background signal [29]. Thus, the TBR was calcu-
lated for each dose, using an area of abdominal muscle as background
(231 § 039, 277 § 097, 328 § 012 and 317 § 023 respec-
tively) demonstrating the highest TBR with 3 mg/g CD24-AF750 dose
(p = 0.0142; Fig. 3(b)).The overall increase in liver to background ratio
(216 § 037, 186 § 031, 243 § 053 and 249 § 008 respec-
tively) with increasing dose in vivo resulted in a decreasing tumour
to liver ratio (110 § 028, 162 § 054, 139 § 029 and
127 § 005 respectively), suggesting saturated receptors andaoperative in vivo white light (colour) image, near infrared (NIR 800) fluorescent image
0 xenograft models injected with 1, 2, 3 or 4 mg/g of CD24-AF750 48 h before imaging.
-AF750 mean fluorescence intensity (MFI) (p = 0.0288 for 1 mg vs 2 mg; p = 0.0112 for
for 1 mg vs 4 mg) of the in vivo primary tumour between the four different doses. (c) Ex
our, kidney and liver (all marked by white dashed line) and (d) comparison of ex vivo
nalysis (one-way ANOVA with unpaired MannWhitney U test) with p < 005 (*) were
8 K. Kleinmanns et al. / EBioMedicine 56 (2020) 102783clearance (Supplementary Fig. S3c). The MFI of the primary tumour,
liver and kidneys were measured ex vivo (Fig. 3(c)), confirming an
increase with dose (primary tumour: 596 § 224, 2973 § 1521,
3924 § 3693 and 6428 § 3409; liver: 1008 § 744,
3251 § 1741, 4860 § 679 and 5611 § 700; and kidneys
030 § 038, 736 § 857, 1519 § 390 and 1923 § 438)
(p = 0.0222; Fig. 3(d)). Ex vivo optical BLI and FLI confirmed fluores-
cence specificity (Supplementary Fig. S3d). Based on the TBR calcu-
lated in vivo, 3 mg/g CD24-AF750 was employed in all further
preclinical validation of CD24-AF750.
3.3. CD24-targeted FIGS greatly enhanced metastases detection and
resection in vivo
To elucidate the potential clinical utility of CD24-guided FIGS to
improve surgical guidance and increase cytoreduction, we designed a
preclinical survival study comparing white light surgery with CD24-
AF750 intraoperative FIGS. Orthotopic OV-90luc+ xenografts (n = 8
mice per group) underwent cytoreductive surgery on day 29 § 24
after implantation, following determination of disease stage by BLI
imaging (data not shown). Primary tumour resection and complete
ovariohysterectomy was performed in all mice, and visible and
resectable metastases were removed (Fig. 4(a)). BLI was performed
on all the resected lesions, which confirmed fluorescence specificity
from OV-90luc+ tumour tissue. Significantly more tumour lesions
(n = 36) were identified in the CD24-FIGS cohort compared to the
white light surgery group (n = 19; p = 00137). The total weight of
resected metastatic tumour lesions was also significantly higher
(7299 § 10.5 mg vs. 3454 § 1362 mg, p = 00421) in the CD24-
FIGS group (Fig. 4(b)).
Surgical resection time (Control: 925 § 26 min; CD24-FIGS:
1274 § 22 min) was longer in the CD24-FIGS group, but did not dif-
fer significantly (p > 005). The postoperative-surgical mortality rate
for both groups was 25% (2/8). At the first post-surgical BLI time
point, seven days after surgery, the BLI signal had decreased by more
than 58% (042 § 034) in the CD24-FIGS cohort compared to 9%
(091 § 070) in the control group (p > 005) (Fig. 4(c)). Both groups
developed an increased tumour burden at subsequent imaging time
points, with a disease latency of four to six weeks, but the BLI signal
of the CD24-FIGS cohort was consistently lower than that of the con-
trol group (Fig. 4(c)). To evaluate if disease stage at the time of sur-
gery impacted the post-surgical outcome in the ovarian xenograft
models, we developed a preclinical staging system, modified from
the FIGO staging classification (Fig. 4(d)), as described earlier. The
majority of the mice were in stage II and III at the time debulking sur-
gery was performed. In mice with stage I disease, the post-surgical
BLI values were almost zero, indicating close to complete cytoreduc-
tion in both groups (Fig. 4(e), Supplementary Fig. S4). CD24-FIGS had
the highest impact during debulking surgery in stage II of our model
(Fig. 4(f), Supplementary Fig. S4). Mice allocated to stage III had
tumour lesions that were unresectable at the time of debulking sur-
gery, and therefore the decrease in the average bioluminescence
intensity was only minor in both cohorts (Fig. 4(g), Supplementary
Fig. S5).
3.4. Verification of CD24-AF750 targeting ability in heterogeneous
patient-derived xenograft models
CD24-guided FIGS greatly improved the detection of metastases in
our orthotopic xenograft model of HGSOC. To further verify the trans-
lational potential of CD24-AF750 for intraoperative guidance during
debulking surgery in ovarian cancer, we imaged four different, clini-
cally annotated orthotopic PDX models of metastatic HGSOC with
heterogeneous CD24 expression (n = 10). After injection with 3 mg/g
CD24-AF750 48 h prior to intraoperative fluorescence imaging,
CD24-AF750 specifically identified the primary tumour and smallmetastatic tumour lesions in the omental tissues, liver, intestines and
diaphragm in the various PDX models, and ex vivo FLI confirmed fluo-
rescence signal specificity (Fig. 5(a)). CD24 expression in PDX fluores-
cence positive lesions was confirmed by IHC, with IRS ranging from 4
to 6 (44 § 11, score; low = 17 = high), demonstrating heteroge-
neous expression in PDX tumour lesions. CK8 staining confirmed
human tumour origin (Fig. 5(b)). IHC staining against folate receptor
alpha was performed to compare the expression to that of CD24 in
the patient-derived tumours, demonstrating comparable IRS (p >
005, n = 21) (Fig. 5(c)). Intraoperative CD24-guided FIGS in ortho-
topic PDX models of metastatic HGSOC, representing patient tumour
heterogeneity and dissemination, allow for specific identification of
primary tumours and small metastatic lesions.
4. Discussion
Physiological CD24 expression is restricted to pre-B-cells, neutro-
phils and stem cells in healthy tissues and has been correlated with
higher self-renewal ability, chemotherapy resistance, omental, peri-
toneal and lymph node metastasis and decreased survival in HGSOC
[24,30,31]. Coupled with an abnormal upregulation of CD24 in multi-
ple human carcinoma (68% and more specifically, 91% in ovarian car-
cinomas), has prompted its exploitation as a therapeutic biomarker
[3234]. Consequently, several reports have described therapeutic
approaches including CAR [35], antibody conjugates [36,37], and bis-
pecific antibodies [38] targeting CD24. Here we demonstrate the suit-
ability of a CD24 antibody conjugate (CD24-AF750) for intraoperative
FIGS in clinically relevant models of HGSOC, supporting its potential
for translation in the intraoperative setting for ovarian cancer
patients. Apart from methylene blue and indocyanine green, which
have relatively low quantum yields and strong non-specific binding
[39] no NIR fluorescent contrast agents have received clinical
approval yet. Although the NIR fluorophore IRDye 800CW conjugated
to clinically approved theragnostic monoclonal antibodies is cur-
rently in clinical trials [13,14] there is no evidence of the superiority
of any NIR contrast agent yet. We chose Alexa Fluor 750 based on the
spectral properties (quantum yield, molar extinction coefficient and
Stokes shift), along with its compatibility with the spectral sensitivity
of our image guided surgery system.
One of the major challenges in application of murine models to
the FIGS setting is in the clinical relevance of the model. Typically,
researchers have applied subcutaneous xenograft models to validate
targeted imaging approaches, however, these models have little to
no clinical relevance in disseminated cancers [20,21,23]. Ceppi et al.
addressed this limitation by utilising an intraperitoneal ovarian can-
cer xenograft model to demonstrate the survival advantage of target-
ing SPARC in the FIGS setting [22]. We have previously developed a
surgically relevant orthotopic model of HGSOC [26,40]. In the current
study we build upon this by employing OV-90luc+ and PDX orthotopic
xenograft models, where disease dissemination better mimics clinical
characteristics of HGSOC [25]. To increase the clinical translatability
of our work we introduce a preclinical staging system based on FIGO
staging used clinically in EOC patients (Fig. 4(d)) and utilise pre-sur-
gery whole-body BLI for surgical planning.
FIGS employing CD24-AF750 permitted detection of significantly
more metastases (473%) compared to guidance by white light and
palpation alone in OV-90luc+ orthotopic xenograft models. At the
optimal dose of 3 ug/ug, CD24-AF750 FIGS could also identify primary
and metastatic lesions in orthotopic PDX models with heterogeneous
CD24 expression. Orthotopic PDX models can provide a good indica-
tion of how well the tracer will perform in a heterogenous human
cancer patient population, however, one limitation to this model is
that non-specific uptake of the tracer cannot be accurately assessed
when the target is human specific [14]. Pre-surgical BLI was found to
correlate well with observed intraoperative disease dissemination,
and mice in our preclinical stage I and II (Fig. 4(d)) could have
Fig. 4. Survival surgery in OV-90luc+ orthoptic xenografts. (a) Intraoperative white light (colour), near infrared (NIR 800) fluorescent and pseudo-coloured fluorescence intensity
merge images from CD24-targeted fluorescence image-guided surgery (FIGS) of the primary ovarian tumour and intra-abdominal metastases. Ex vivo bioluminescence imaging was
performed on resected lesions to confirm tumour specificity. (Scale bars = 1 cm). (b) Comparison of the number and total weight of resected metastatic lesions between the CD24
FIGS cohort (n = 8) and white light control surgery (n = 8). (c) Comparison of post-operative bioluminescence signal intensity between CD24-FIGS resected mice (n = 6) and white
light control mice (n = 6). Longitudinal whole-body bioluminescence imaging was performed weekly for four weeks post-surgery and the bioluminescent signal was normalised to
the presurgical bioluminescence signal of each individual mouse. (d) Mice were allocated a disease stage based on pre-surgical bioluminescence signal and intraoperative disease
dissemination (e) Comparison of (normalised) pre- and post-surgical bioluminescence signal between CD24-FIGS and white light surgery in Stage I (f) Stage II and (g) Stage III
resected mice (p > 005). Statistical analysis (MannWhitney U test) with p < 005 (*) were regarded as statistically significant.
K. Kleinmanns et al. / EBioMedicine 56 (2020) 102783 9satisfactory tumour resections, highlighting the utility of a CD24 tar-
geted approach for FIGS in HGSOC. However, the small size of rodents
makes debulking surgery technically challenging, and certain proce-
dures, for instance intestinal resection with end-to-end anastomosis,
impossible. Subsequently, mice with metastases on vital organs couldnot undergo resection resulting in similar debulkment results
between CD24-FIGS and controls at stage III (Fig. 4(g), Supplementary
Fig. S4). These results, however, are not reflective of the efficacy of
CD24-AF750 tumour delineation, but rather highlight the disadvan-
tage of mouse models for surgical applications. Thus, future
Fig. 5. Intraoperative CD24-targeted fluorescence imaging of four heterogeneous PDX of advanced stage HGSOC. (a) Intraoperative white light (colour), near infrared (NIR 800) fluo-
rescent and pseudo-coloured fluorescence intensity merge images show positive identification of primary tumour and small metastatic lesions in four separate, orthotopically
implanted PDXmodels of HGSOC, after injection with 3mg/g CD24-AF750 48 h prior to intraoperative fluorescence imaging. Ex vivo optical imaging confirmed fluorescence specific-
ity. Positive lesions are represented by dashed lines in the colour view image. The arrow points to the strongest fluorescent signal in the near infrared (NIR) 800 images. (Scale bar,
1 cm). (b) CD24 expression was confirmed by IHC in fluorescence positive PDX lesions. CD24 staining was evaluated in all five resected lesions with an immunoreactivity score
(44§ 11, scale: low 1 7 high). CK8 staining was used to confirm human tumour origin. Magnification 200£. (c) CD24 and folate receptor alpha IHC immunoreactivity score com-
parison on PDX tissue sections, demonstrating no significance (p > 005, MannWhitney U test)) difference (n = 21). Images were captured at 100£ and 200£magnification (scale
bar = 25mm).
10 K. Kleinmanns et al. / EBioMedicine 56 (2020) 102783preclinical development of FIGS probes should also consider compan-
ion animal models as an ethically attractive large animal alternative
[41]. Veterinary clinical trials in pet dogs with naturally occurring
cancer can accelerate the definition of safety profiles and biological
activity of new tumour targeted fluorescent probes and fill the gap
between the laboratory animal models and early-phase clinical stud-
ies in patients [42].
As demonstrated by van Dam et al. in 2011, intraoperative tumour-
targeted fluorescence image-guided surgery has the potential to
improve the degree of cytoreduction and improve survival in patients
with advanced ovarian cancer [16,18,19]. While FR demonstrates high
expression in EOC, it is not expressed ubiquitously in all EOC patients.
Indeed, a study of tumour samples from 2801 patients in the OvarianTumour Tissue Analysis (OTTA) consortium found FR expression ranged
from 76% in HGSOC to 11% in mucinous carcinomas [43]. While no such
studies have investigated CD24 expression in such a large patient
cohort, this data highlights the need for additional targets for FIGS
applications in clinically heterogeneous cohorts. Furthermore, FR
expression is associated with increased overall survival [43], with no
major changes in receptor expression in matched pre- and post-treat-
ment biopsy samples [44]. In contrast, CD24 is a known cancer stem
cell marker [24], promotes motility and metastasis [45] and is a predic-
tor of tumour recurrence [46]. Thus, a CD24 targeted FIGS probe could
bemultiplexedwith a FRa contrast reagent to increase tumour delinea-
tion in primary cytoreductive surgery. Finally, CD24 FIGS probe could
be an excellent candidate for secondary debulkment protocols [47].
K. Kleinmanns et al. / EBioMedicine 56 (2020) 102783 11We have demonstrated that CD24-targeted fluorescence image-
guided surgery significantly improved cytoreduction in clinically rel-
evant orthotopic models of high-grade serous ovarian carcinoma,
and we have demonstrated the ability of CD24-AF750 to identify
metastatic lesions in various heterogenous patient-derived xenograft
models. The addition of CD24 as a promising biomarker for the appli-
cation of fluorescence-guided surgery can aid further delineation of
metastases and be of greater benefit to ovarian cancer patients with
poor prognosis.
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